FDA approves Moderna's mRNA flu vaccine for adults aged 50 and above

The FDA has approved Moderna's mFLUSIVA, the first mRNA vaccine for influenza, specifically for adults 50 and older. Studies showed this new mRNA shot to be 27% more effective than traditional flu vaccines in preventing flu cases. This approval marks a significant advancement in flu prevention technology and is expected to be available this fall, with Medicare and Medicaid coverage anticipated.